- Design
- Phase 3, randomised, double-blind, placebo-controlled crossover
- Population
- 134 people aged 12–75 with hereditary angioedema; 88 with paired attacks
- Primary outcome
- Time to onset of symptom relief
- Effect
- Median 1.28 h (95% CI 1.05–1.52) vs >12 h; P<0.0001
RAPIDe-3 was a phase 3 double-blind crossover trial at 59 sites in 24 countries. People aged 12–75 with hereditary angioedema treated two attacks, one with oral deucrictibant 20 mg, a bradykinin B2 receptor antagonist, and one with placebo.
In the 88 participants with paired attacks, median time to symptom relief was 1.28 hours with deucrictibant against more than 12 hours with placebo. No treatment-related adverse events were severe or serious, and none led to stopping treatment.
Current on-demand options are injected or infused. A capsule that can be taken at the first sign of an attack would matter to patients. The trial by itself does not make the drug available; check its approval status locally before expecting access.
- Check local approval status before discussing deucrictibant; established on-demand treatments remain the standard meanwhile.
- Median relief came at about 1.3 hours with the oral drug.
- Laryngeal attacks still need emergency assessment whatever the patient carries.
- Hereditary angioedema does not respond to antihistamines or adrenaline in the usual way — recognise it in the emergency department.
Why it matters
A tablet taken at the first symptom could shorten attacks for patients who now delay injecting.
Don't overread it
The comparison was with placebo, not with existing injectable treatments.
The statistics, in plain English
In a crossover trial each person acts as their own control, which needs fewer participants. A median of 'more than 12 hours' means over half the placebo-treated attacks had not improved by the end of the observation window.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for top clinical updates, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free